Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors

International Journal of Cancer

Volumn 66, Issue 3, 1996, Pages 305-308

  Sato, Kazufumi ^a   Schäuble, Barbara ^b   Kleihues, Paul ^a,b   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P15; PROTEIN P16; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CDK4 GENE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BASE SEQUENCE; BLOTTING, SOUTHERN; BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA PRIMERS; EPENDYMOMA; HUMANS; MEDULLOBLASTOMA; MENINGEAL NEOPLASMS; MENINGIOMA; MOLECULAR SEQUENCE DATA; NEUROECTODERMAL TUMORS; OLIGODENDROGLIOMA; OLIGONUCLEOTIDE PROBES; ONCOGENE PROTEINS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; REFERENCE VALUES;

EID: 0029884472     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960503)66:3<305::AID-IJC6>3.0.CO;2-2     Document Type: Article

References (30)

1. CORDON-CARDO, C., Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Amer. J, Pathol., 147, 545-560 (1995).
2. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371, 6338-6339 (1994).
3. HAYASHI, N., SUGIMOTO, Y., TSUCHIYA, E., OGAWA, M. and NAKAMLRA, Y., Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem biophys. Res. Comm., 202, 1426-1430 (1994).
4. HE, J., ALLEN. J.R., COLLINS, V.P., ALLALUNIS TURNER, M.J., GODBOUT, R., DAY, R.S. and JAMES, C.D., CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54, 5804-5807 (1994).
5. HUSSUSSIAN, C.J., STRUEWING, J.P., GOLDSTEIN, A.M., HIGGINS, P.A., ALLY, D.S., SHEARAN, M.D., CLARK, W.H., JR., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature (Genet.), 8, 15-21 (1994).
6. JEN, J., HARPER, J.W., BIGNER, S.H., BIGNER, D.D., PAPADOPOULOS, N., MARKOWITZ, S., WILLSON, J.K., KINZLER, K.W. and VOGELSTEIN. B., Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54, 6353-6358 (1994).
7. JIANG, W., ZHANG, Y.J., KAHN, S.M., HOLLSIKIN, M.C., SANTELLA, R.M., LU, S., HARRIS, C.C., MONTESANO, R. and WEINSTEIN, I.B., Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. nat. Acad. Sci. (Wash.), 90, 9026-9030 (1993).
8. KAMB, A., GRUIS, N.A., WEAVER FELDRAUS, J., LIU, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY, R.S., JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
9. KHATIB, Z.A., MATSUSHIME, H., VALENTINE, M., SHAPIRO, D.N., SHERR, C.J. and LOOK, A.T., Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53, 5535-5541 (1993).
10. KLEIHUES, P., BURGER, P.C. and SCHEITHAUER, B.W., Histological typing of tumours of the central nervous system. World Health Organization International Histological Classification of Tumours. Springer, Berlin (1993).
11. KOH, J., ENDERS, G.H., DYNLACHT, B.D. and HARLOW, E., Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond), 375, 506-510 (1995).
12. KRAUS, J.A., KOOPMANN, J.. KASKEL, P., MAINTZ, D., BRASDNER, S., SCHRAMM, J., LOUIS, D.N., WIESTLER, O.D. and VON DEIMLING, A., Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol. exp. Neurol., 54, 91-95 (1995).
13. Li, Y., NICHOLS, M.A, SHAY. J.W. and XIONG, Y., Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54, 6078-6082 (1994).
14. MCDONALD, J.D., DANESHVAR, L., WILLERT, J.R., MATSUMURA, K., WALDMAN, F. and COGEN, P.H., Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma Genomics, 23, 229-232 (1994).
15. MORI, T., MIURA, K., AOKI, T., NISHIHIRA, T., MORI, S. and NAKAMURA, Y., Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor, cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397 (1994).
16. INK4 expression is frequent in high grade gliomas. Cancer Res., 55, 1941-1945 (1995).
17. NOBORI, T., MIURA, K., WU, D.J., LOIS, A., TAKABAYASHI, K. and CARSON, D.A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368, 753-756 (1994).
18. OHGAKI, H., EIBL, R.H., SCHWAB, M., REICHEL, M.B., MARIANI, L., GEHRING, M., PETERSEN, I., HOLL, T., WIESTLER, O.D. and KLEIHUES. P., Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol. Carinogenesis, 8, 74-80 (1993).
19. OHGAKI, H., EIBL, R.H., WIESTLER, O.D., YASARGIL, M.G., NEWCOMB, E.W. and KLEIHUES, P., p53 mutations in nonastrocytic human brain tumors. Cancer Res., 51, 6202-6205 (1991).
20. OHGAKI, H., SCHAUBLE, B., ZUR HAUSEN, A., VON AMMON, K. and KLEIHUES, P., Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch., 427, 113-118 (1995).
21. INK4B/JWTS2 in human leukemias and lymphomas. Cancer Res., 55, 1436-1440 (1995).
22. ROGATTO, S.R., CASARTELLI, C., RAINHO, C.A. and BARBIERI-NETO. J., Chromosomes in the genesis and progression of ependymomas. Cancer Genet. Cytogenet., 69, 146-152 (1993).
23. RUBIO, M.P., CORREA, K.M., RAMESH, V., MACCOLLIN, M.M., JACOBY, L.B., VON DEIMLING, A., GUSELLA, J.F. and Louis, D.N., Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res., 54, 45-47 (1994).
24. SCHMIDT, E.E., ICHIMURA, K., REIFENBERGER, G. and COLLINS. V.P., CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of gliobtastomas. Cancer Res., 54, 6321-6324 (1994).
25. SCHOFIELD, D., WEST, D.C., ANTHONY, D.C., MARSHAL, R. and SKLAR, J., Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Amer. J. Pathol., 146, 472-480 (1995).
26. SERRANO, M., HANNON, G.J. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond), 336, 704-707 (1993).
27. SPRUCK, C.H., GONZALEZ ZULUETA, M., SHIBATA, A., SIMONEAU, A.R., LIN, M.F., GONZALES, F., TSAI, Y.C. and JONES, P.A., p16 gene in uncultured tumours. Nature (Lond.), 370, 183-184 (1994).
28. SUN, Y., HILDESHEIM, A., LANIER, A.E., CAO, Y., YAO, K.T., RAAB TRAUB, N. and YANG, C.S., No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas. Oncogene, 10, 785-788 (1995).
29. UEKI, K., RUBIO, M.-P., RAMESH, V., CORREA, K.M., RUTTER, J.L., VON DEIMLING, A., BUCKLER, A.J., GUSELLA, J.F. and Louis, D.N., MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum. mol. Genet., 3, 1841-1845 (1994).
30. WELLENREUTHER, R., KRAUS, J.A., LENARTZ, D., MENON, A.G., SCHRAMM, J., LOUIS, D.N., RAMESH, V., GUSELLA, J.F., WIESTLER, O.D. and VON DEIMLING, A., Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Amer. J. Pathol., 146, 827-832 (1995).